Table 3. PR of eight minimally invasive surgeries in unresectable HCC according to the network meta-analysis using odds ratios (ORs) and corresponding 95% credible intervals (CrIs).

DEB-TACE	0.61 (0.20, 1.74)	3.53 (0.32, 34.46)	0.93 (0.07, 10.23)	0.28 (0.03, 2.88)	1.12 (0.11, 8.73)	0.74 (0.15, 3.51)	0.63 (0.03, 10.20)
1.63 (0.58, 5.08)	TACE	5.66 (0.66, 45.59)	1.50 (0.16, 14.16)	0.46 (0.06, 3.77)	1.81 (0.26, 11.14)	1.21 (0.41, 4.05)	1.03 (0.07, 14.77)
0.28 (0.03, 3.10)	0.18 (0.02, 1.52)	TACE+EBRT	0.27 (0.01, 6.23)	0.08 (0.00, 1.60)	0.32 (0.02, 4.89)	0.21 (0.02, 2.63)	0.18 (0.01, 5.58)
1.07 (0.10, 13.39)	0.67 (0.07, 6.10)	3.76 (0.16, 82.86)	TACE+HIFU	0.30 (0.02, 6.36)	1.18 (0.06, 19.92)	0.80 (0.07, 10.45)	0.68 (0.02, 19.78)
3.59 (0.35, 38.27)	2.20 (0.27, 17.77)	12.51 (0.63, 233.52)	3.31 (0.16, 65.73)	TACE+PEI	4.07 (0.21, 58.33)	2.68 (0.26, 29.01)	2.25 (0.07, 64.38)
0.90 (0.11, 9.13)	0.55 (0.09, 3.91)	3.09 (0.20, 53.86)	0.85 (0.05, 16.49)	0.25 (0.02, 4.73)	TACE+SOR	0.68 (0.08, 6.83)	0.56 (0.02, 14.89)
1.35 (0.29, 6.49)	0.83 (0.25, 2.44)	4.69 (0.38, 48.45)	1.26 (0.10, 15.27)	0.37 (0.03, 3.83)	1.48 (0.15, 12.07)	TARE-90Y	0.85 (0.04, 14.95)
1.60 (0.10, 28.84)	0.97 (0.07, 14.08)	5.56 (0.18, 165.28)	1.47 (0.05, 50.56)	0.44 (0.02, 13.84)	1.77 (0.07, 45.74)	1.18 (0.07, 24.57)	TEA

^*DEB-TACE: drug-eluting beads-transcatheter arterial chemoembolization; SOR: sorafenib; TACE: transcatheter arterial chemoembolization; EBRT: external-beam radiation therapy; HIFU: high intensity focused ultrasound; PEI: percutaneous ethanol injection; TARE-90Y: yttrium-90 radioembolization; TEA: transarterial ethanol ablation.